Literature DB >> 16651866

Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.

Peter A von dem Borne1, Linda M P Cox, Bonno N Bouma.   

Abstract

In-vitro studies have shown that thrombin-mediated factor XI activation enhances thrombin and fibrin formation, rendering the clot more thrombogenic and protecting it from lysis by activation of thrombin activatable fibrinolysis inhibitor. These effects of factor XI are only observed when coagulation is initiated by a low concentration of soluble tissue factor. At high concentrations of soluble tissue factor no effects of factor XI are seen on coagulation and fibrinolysis. In vivo, tissue factor is present in large amounts in the vascular wall. This makes it difficult to extrapolate these in-vitro findings on factor XI to the in-vivo situation. To address the question of whether factor XI could play a role in coagulation initiated on a tissue factor-containing surface we devised a static in-vitro coagulation model in which clotting is initiated in recalcified citrated plasma by tissue factor coated on the bottom of microtiter plates. The effect of factor XI was studied with an antibody that blocked the activation of factor IX by activated factor XI. The tissue factor coating strategy produced clotting times similar to those obtained with cultured tissue factor-expressing vessel wall cells (smooth muscle cells, fibroblasts and activated endothelial cells) grown to confluence in the same wells. A factor XI-dependent effect on clot formation and clot lysis was observed depending on the plasma volume used. In clots formed from small amounts of plasma (100 microl) no effect of factor XI was detected. In larger clots (200-300 microl) factor XI not only increased prothrombin activation and the fibrin formation rate but also inhibited fibrinolysis. Effects of factor XI were observed at short clotting times (3-4 min) similar to the clotting times found on cultured tissue factor-expressing vessel wall cells. This is in contrast with earlier studies using soluble tissue factor, in which effects of factor XI were only observed at much longer clotting times using low soluble tissue factor concentrations. We conclude that factor XI not only enhances coagulation initiated by surface bound tissue factor but also protects the clot against lysis once it is formed. On the basis of these results, we propose a coagulation model in which initial clot formation in the proximity of the tissue factor surface is not factor XI dependent. Clot formation becomes dependent on factor XI in the propagation phase when the clot is increasing in size. These findings support a role for factor XI in the propagation of clot growth after tissue factor-dependent initiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651866     DOI: 10.1097/01.mbc.0000224843.33216.5f

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  10 in total

1.  Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events.

Authors:  Anetta Undas; Agnieszka Slowik; Matthew Gissel; Kenneth G Mann; Saulius Butenas
Journal:  Eur J Clin Invest       Date:  2011-06-27       Impact factor: 4.686

2.  Correlation between factor (F)XIa, FIXa and tissue factor and trauma severity.

Authors:  Shannon M Prior; Mitchell J Cohen; Amanda S Conroy; Mary F Nelson; Lucy Z Kornblith; Benjamin M Howard; Saulius Butenas
Journal:  J Trauma Acute Care Surg       Date:  2017-06       Impact factor: 3.313

3.  Blood clot formation under flow: the importance of factor XI depends strongly on platelet count.

Authors:  Aaron L Fogelson; Yasmeen H Hussain; Karin Leiderman
Journal:  Biophys J       Date:  2012-01-03       Impact factor: 4.033

4.  Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation.

Authors:  Karin Leiderman; William C Chang; Mikhail Ovanesov; Aaron L Fogelson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-27       Impact factor: 8.311

5.  Tranexamic acid-loaded starch hemostatic microspheres.

Authors:  Huantong Su; Shuda Wei; Fangping Chen; Ruihua Cui; Changsheng Liu
Journal:  RSC Adv       Date:  2019-02-21       Impact factor: 4.036

6.  Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Mary Cushman; Ellen S O'Meara; Aaron R Folsom; Susan R Heckbert
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

7.  Contact pathway of coagulation and inflammation.

Authors:  Yi Wu
Journal:  Thromb J       Date:  2015-05-06

8.  Activated Factor XI is Increased in Plasma in Response to Surgical Trauma but not to Recombinant Activated FVII-Induced Thrombin Formation.

Authors:  Heiko Rühl; Anne M Friemann; Sara Reda; Nadine Schwarz; Franziska I Winterhagen; Christina Berens; Jens Müller; Johannes Oldenburg; Bernd Pötzsch
Journal:  J Atheroscler Thromb       Date:  2020-12-09       Impact factor: 4.928

9.  Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD.

Authors:  Michael Walsh; Claudette Bethune; Andrew Smyth; Jessica Tyrwhitt; Shiangtung W Jung; Rosie Z Yu; Yanfeng Wang; Richard S Geary; Jeffrey Weitz; Sanjay Bhanot
Journal:  Kidney Int Rep       Date:  2021-11-24

Review 10.  Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications.

Authors:  Diana A Gorog
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.